Semaglutide and Heart Disease: The SELECT Trial

The link between semaglutide and heart disease was settled by the SELECT trial, which showed that semaglutide 2.4 mg (sold as Wegovy) cut the risk of major adverse cardiovascular events by roughly 20% in adults who had established cardiovascular disease and overweight or obesity but did not have diabetes. That result, published in the New England Journal of Medicine in 2023, was a landmark: it was the first time a medicine prescribed for weight loss was shown to also protect the heart in an outcomes trial. It led the U.S. Food and Drug Administration to approve Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in that population, a first for any weight-loss drug. This guide explains what SELECT measured, who it studied, why the benefit looks bigger than weight loss alone can account for, and where the caveats are.

What the SELECT trial was

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a large, randomized, double-blind, placebo-controlled trial run across dozens of countries. It enrolled more than 17,000 adults aged 45 and older who had a body mass index of 27 or higher and established cardiovascular disease, meaning a prior heart attack, prior stroke, or symptomatic peripheral artery disease. Importantly, people with type 1 or type 2 diabetes were excluded. That design point matters, because it isolated the question almost no one had answered before: in people carrying excess weight and known heart disease but not diabetes, does semaglutide change hard cardiovascular outcomes, not just the number on the scale?

Participants were randomly assigned to once-weekly semaglutide titrated up to 2.4 mg (the same dose used for weight management) or to a matching placebo, both on top of standard cardiovascular care such as statins, blood pressure drugs, and antiplatelet therapy. They were followed for an average of more than three years, which is long enough for heart attacks and strokes to accumulate and be counted. The semaglutide molecule itself is the same GLP-1 receptor agonist used across the brand, and we cover the underlying biology in how semaglutide works for weight loss.

What SELECT measured and what it found

The primary endpoint was a composite of three serious events, often called MACE (major adverse cardiovascular events): cardiovascular death, non-fatal heart attack, and non-fatal stroke. The table below summarizes the core of the trial.

What SELECT measured	Result
Who was studied	~17,600 adults, BMI 27+, established CVD, no diabetes
Treatment	Semaglutide 2.4 mg weekly vs placebo, on top of standard care
Average follow-up	About 3.3 years
Primary endpoint (MACE)	Cardiovascular death, non-fatal heart attack, non-fatal stroke
Headline result	~20% relative reduction in MACE vs placebo
Average weight change	About 9 to 10% body weight lost on semaglutide
Tolerability	More GI side effects and discontinuations than placebo; no new safety signal

The roughly 20% relative risk reduction was statistically significant and consistent across the components of the composite. In plain terms, fewer people in the semaglutide group had a heart attack, a stroke, or died of a cardiovascular cause over the course of the trial. The participants also lost about 9 to 10% of their body weight on average, less than the roughly 15% seen in the pure weight-loss trial of the same dose, which makes sense given an older, sicker population. Side effects followed the familiar GLP-1 pattern, gastrointestinal and concentrated early, and more people stopped semaglutide than placebo because of them, but no unexpected safety problem emerged.

Why the benefit looks bigger than the weight loss

One of the most discussed findings from SELECT is that the cardiovascular benefit appeared to be at least partly independent of how much weight each person lost. The event curves for semaglutide and placebo began to separate early, within the first months, before large amounts of weight had come off, and the benefit did not track tightly with the amount of weight an individual lost. That pattern suggests semaglutide is doing more for the heart than simply shrinking body fat.

Researchers think several mechanisms beyond weight reduction may contribute. Semaglutide lowers blood pressure modestly, reduces markers of inflammation such as C-reactive protein, improves blood sugar and lipid measures, and may act directly on blood vessels and the heart. GLP-1 receptors are present in the cardiovascular system, and the drug class has effects on vascular function that are still being mapped. The honest summary is that the exact mix is not fully understood, but the data point to a combination of weight loss plus direct cardiometabolic effects rather than weight loss alone. The pharmacology behind those effects is reviewed in the foundational GLP-1 mechanism literature, and we summarize the basics in how semaglutide works.

What it means for patients

For a specific group of patients, SELECT changed the conversation. If you have established heart disease and carry excess weight, semaglutide is now a drug that can both help you lose weight and lower your risk of a future heart attack or stroke. That is a meaningful shift, because it reframes the medicine from a cosmetic or metabolic tool into a cardiovascular one, similar in spirit to how statins are prescribed to prevent events rather than to change a lab number for its own sake.

The FDA acted on this. In 2024 it approved Wegovy with an added indication: reducing the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight. That approval also matters practically, because a recognized cardiovascular indication can strengthen the case for insurance coverage, including some movement on Medicare, which we track in does Medicare cover GLP-1. For how the brand fits among approved options, see FDA-approved GLP-1 medications, and for the brand split between the diabetes and weight-loss versions of semaglutide, see Ozempic vs Wegovy.

How this compares to tirzepatide

The obvious next question is whether tirzepatide (Zepbound and Mounjaro), the dual GLP-1/GIP drug that produces more weight loss, offers the same heart protection. The honest answer in 2026 is that the cardiovascular outcomes data for tirzepatide are still maturing. Tirzepatide's weight-loss credentials are strong: SURMOUNT-1 showed up to roughly 20.9% mean weight loss at the top dose, more than semaglutide delivers. But a large dedicated cardiovascular outcomes trial in people without diabetes, the equivalent of SELECT, has not yet reported in full, so tirzepatide does not currently carry an FDA approval to reduce cardiovascular events.

	Semaglutide 2.4 mg (Wegovy)	Tirzepatide (Zepbound)
Drug class	GLP-1 agonist	Dual GLP-1 / GIP agonist
Mean weight loss (trial)	~15% (STEP-1)	~20.9% (SURMOUNT-1)
CV outcomes trial	SELECT, reported, positive	Still maturing
FDA cardiovascular indication	Yes (2024)	Not yet

So the trade-off, as of now, is that tirzepatide tends to take off more weight while semaglutide has the proven, approved heart-protection evidence base. That can flip if tirzepatide's outcomes trials report positively, which many clinicians expect, but evidence-based practice means going on what has actually been shown. We compare the two molecules in depth in GLP-1 weight loss results by drug and the brand head-to-head in Wegovy vs Zepbound.

The caveats worth keeping in mind

SELECT is a strong trial, but its result applies to the people it studied, and over-reading it is a real risk. A few limits matter:

• It was secondary prevention. Every participant already had cardiovascular disease. SELECT does not show that semaglutide prevents first-ever heart attacks in otherwise healthy people with obesity, so it is not evidence for primary prevention across the board.
• It excluded diabetes. The benefit in people with diabetes is supported by separate trials of semaglutide, but SELECT itself was specifically a non-diabetes population.
• The number is a relative reduction. A roughly 20% relative reduction in risk is not the same as a 20-point drop in everyone's absolute risk; the absolute benefit depends on how high your starting risk is.
• It is a treatment you stay on. The trial tested ongoing weekly dosing. The protective effect is tied to continued use, and stopping reverses much of the weight loss, as covered in our results index.
• Side effects are real. More people stopped semaglutide than placebo because of gastrointestinal effects, so tolerability is part of the equation, and we cover managing it in the side-effects material.

None of this diminishes the headline. It just keeps it in scope: this is a heart-protection benefit for adults who have both excess weight and established cardiovascular disease, prescribed and monitored by a clinician, not a blanket reason for everyone to take the drug. Whether you fit the criteria at all is a separate threshold question, covered in who qualifies for a GLP-1 prescription.

Where this leaves semaglutide and heart disease

The story of semaglutide and heart disease is now one of the more important results in obesity medicine. For decades, weight-loss drugs were judged almost entirely on pounds lost, and several earlier ones were pulled for harming the heart. SELECT inverted that history by showing a weight medicine that measurably protects it. The benefit is partly but not entirely explained by weight loss, the FDA has recognized it for a defined population, and the comparable data for tirzepatide are still coming. For the right patient, that makes semaglutide a genuinely different proposition: a treatment chosen not only for the scale, but for the heart. Because it is a prescription decision with meaningful trade-offs, it belongs in a conversation with a licensed clinician or telehealth provider who can weigh your cardiovascular history alongside your weight goal.